Key facts
- Lentitek’s last known valuation is $3.8M (Feb 2025).
- It has raised $1.2M; the latest was Angel (individual) ($860K) in Feb 2025.
- Notable investors include Innovate UK, Scottish Enterprise, Apollo Informal Investment, Equity Gap, Gabriel Investment Syndicate — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Lentitek
- ·The full record, as it builds
Funding rounds
No funding rounds for Lentitek are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lentitek
Developer of gene therapies and gene-modified cell therapies designed to increase lentiviral production yields. The company's platform offers a novel promoter with a proprietary method for producing lentivirus that could improve and enhance the yield of lentiviral vectors, enabling healthcare providers to reduce production costs through triple transfection production.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2019
- Employees
- 9
- Website
- lentitek.com/
- Ownership
- Privately Held (backing)
Lentitek doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lentitek shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lentitek in its N-PORT filings yet. We sweep new filings monthly.